Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
Ryosuke Hino, Kenji Kabashima, Yu Kato, et al.
Cancer (2010) Vol. 116, Iss. 7, pp. 1757-1766
Open Access | Times Cited: 640

Showing 1-25 of 640 citing articles:

The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
Nature reviews. Cancer (2012) Vol. 12, Iss. 4, pp. 252-264
Open Access | Times Cited: 12406
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, et al.
New England Journal of Medicine (2012) Vol. 366, Iss. 26, pp. 2455-2465
Open Access | Times Cited: 7481
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel, Razelle Kurzrock
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 4, pp. 847-856
Closed Access | Times Cited: 2040
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube, Robert A. Anders, Geoffrey D. Young, et al.
Science Translational Medicine (2012) Vol. 4, Iss. 127
Open Access | Times Cited: 2008
CTLA-4 and PD-1 Pathways
Elizabeth I. Buchbinder, Anupam M. Desai
American Journal of Clinical Oncology (2015) Vol. 39, Iss. 1, pp. 98-106
Open Access | Times Cited: 1947
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green, Stefano Monti, Scott J. Rodig, et al.
Blood (2010) Vol. 116, Iss. 17, pp. 3268-3277
Open Access | Times Cited: 1210
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Judith A. Seidel, Atsushi Otsuka, Kenji Kabashima
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 1188
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 34, pp. 4015-4022
Closed Access | Times Cited: 1076
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin, Marc S. Ernstoff, Omid Hamid, et al.
The Lancet Oncology (2012) Vol. 13, Iss. 5, pp. 459-465
Closed Access | Times Cited: 1063
T-cell exhaustion in the tumor microenvironment
Yuyong Jiang, Yongsheng Li, Bo Zhu
Cell Death and Disease (2015) Vol. 6, Iss. 6, pp. e1792-e1792
Open Access | Times Cited: 897
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
Joseph McLaughlin, Gang Han, Kurt A. Schalper, et al.
JAMA Oncology (2015) Vol. 2, Iss. 1, pp. 46-46
Open Access | Times Cited: 765
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam, Amer Assal, Eszter Lázár‐Molnár, et al.
Trends in Molecular Medicine (2014) Vol. 21, Iss. 1, pp. 24-33
Open Access | Times Cited: 746
PD-L1 expression in human cancers and its association with clinical outcomes
Jinming Yu, Xin Wang, Feifei Teng, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 5023-5039
Open Access | Times Cited: 691
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
Jiezhong Chen, Chen Chen Jiang, Lei Jin, et al.
Annals of Oncology (2015) Vol. 27, Iss. 3, pp. 409-416
Open Access | Times Cited: 689
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green, Scott J. Rodig, Przemysław Juszczyński, et al.
Clinical Cancer Research (2012) Vol. 18, Iss. 6, pp. 1611-1618
Open Access | Times Cited: 639
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen, Bryan Irving, F. Stephen Hodi
Clinical Cancer Research (2012) Vol. 18, Iss. 24, pp. 6580-6587
Closed Access | Times Cited: 605
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero, David M. Berman, M. Ángela Aznar, et al.
Nature reviews. Cancer (2015) Vol. 15, Iss. 8, pp. 457-472
Closed Access | Times Cited: 600
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
Koichi Azuma, Keiichi Ota, Akihiko Kawahara, et al.
Annals of Oncology (2014) Vol. 25, Iss. 10, pp. 1935-1940
Open Access | Times Cited: 596
In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human Primates
Changyu Wang, Kent Thudium, Minhua Han, et al.
Cancer Immunology Research (2014) Vol. 2, Iss. 9, pp. 846-856
Open Access | Times Cited: 555
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney, Gordon J. Freeman, David F. McDermott
Clinical Therapeutics (2015) Vol. 37, Iss. 4, pp. 764-782
Open Access | Times Cited: 533
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
Mario Sznol, Lieping Chen
Clinical Cancer Research (2013) Vol. 19, Iss. 19, pp. 5542-5542
Open Access | Times Cited: 532
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
Simone Muenst, A. R. Schaerli, Feng Gao, et al.
Breast Cancer Research and Treatment (2014) Vol. 146, Iss. 1, pp. 15-24
Open Access | Times Cited: 515
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Kankana Bardhan, Theodora Anagnostou, Vassiliki A. Boussiotis
Frontiers in Immunology (2016) Vol. 7
Open Access | Times Cited: 514
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Mario Sznol, Lieping Chen
Clinical Cancer Research (2013) Vol. 19, Iss. 5, pp. 1021-1034
Open Access | Times Cited: 466
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee‐Shing Chang, Romualdo Barroso‐Sousa, Sara M. Tolaney, et al.
Endocrine Reviews (2018) Vol. 40, Iss. 1, pp. 17-65
Open Access | Times Cited: 439
Page 1 - Next Page

Scroll to top